Nordén, Kristine Røren
Semb, Anne Grete
Dagfinrud, Hanne
Hisdal, Jonny
Ødegård, Sigrid
Sexton, Joseph
Fongen, Camilla
Skandsen, Jon
Blanck, Thalita
Metsios, George S.
Tveter, Anne Therese
Funding for this research was provided by:
EkstraStiftelsen Helse og Rehabilitering (2021/FO347439)
REMEDY - Center for treatment of Rheumatic and Musculoskeletal Diseases (328657, 328657, 328657, 328657, 328657, 328657, 328657, 328657)
Norsk Revmatikerforbund (November 2021, no grant number, November 2021, no grant number)
Article History
Received: 10 February 2023
Accepted: 19 April 2023
First Online: 21 April 2023
Declarations
:
: The ExeHeart trial, including the present study, was granted ethical approval from the Regional Committee for Medical and Health Research Ethics (201227) and the Data Protection Officer at Diakonhjemmet Hospital (reg.no. 00397). All patients signed an informed consent form before participating in the study and all study protocols were performed in accordance with the declaration of Helsinki.
: Not applicable as the present study does not present individual person’s data.
: KRN has received lecture honoraria from UCB. AGS has received lecture honoraria from AbbVie, Novartis, Bayer, Eli Lilly, Pfizer and Sanofi. AGS is secretary of ESC Cardiovascular Pharmacotherapy working group, nucleus member of EACP Risk Factor Management and Primary care nucleus, all gratuitous. GM has received lecture honoraria from Novartis. HD, JH, SØ, JSe, CF, JSk, TB and ATT have nothing to disclose.